SCHEMBL3566538

SCHEMBL3566538

CC(C)(C)NS(=O)(=O)c1cccc(-c2ncn(-c3cc(C(F)(F)F)cc(-c4ccc(C(F)(F)F)cc4)n3)n2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF18A Q8NI77 1/20 0.40
PFKFB3 Q16875 1/20 0.39
JAK2 O60674 1/20 0.38
PTGES2 Q9H7Z7 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM1A O60341 1/20 0.36
NPY5R Q15761 1/20 0.35
HSD11B1 P28845 1/20 0.35
IDH2 P48735 1/20 0.35
THRB P10828 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
TNNI3K Q59H18 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3571306 0.86 PTGS2 (0.41) PFKFB3PTGES2
SCHEMBL3569330 0.84 KIF18A (0.41) KIF18APFKFB3JAK2PTGES2MEN1
SCHEMBL3565356 0.80 KIF18A (0.44) KIF18APFKFB3JAK2PTGES2MEN1
SCHEMBL3562431 0.79 PFKFB3 (0.47) KIF18APFKFB3JAK2PTGES2MEN1
SCHEMBL3559647 0.78 KIF18A (0.42) KIF18APFKFB3JAK2PTGES2MEN1
SCHEMBL3556591 0.77 PFKFB3 (0.46) KIF18APFKFB3JAK2PTGES2MEN1
SCHEMBL3556334 0.77 SYK (0.43) KIF18APFKFB3JAK2PTGES2MEN1
SCHEMBL3565434 0.77 SYK (0.44) KIF18AJAK2PTGES2MEN1KMT2A
SCHEMBL3563110 0.76 KIF18A (0.41) KIF18APFKFB3JAK2PTGES2MEN1
SCHEMBL3563539 0.76 KIF18A (0.44) KIF18APFKFB3PTGES2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 KIF18A 3355/4885PFKFB3 1222/4885JAK2 1623/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 KIF18A 3661/4885PFKFB3 556/4885JAK2 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.